본문바로가기
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
새창열기 아이콘
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
sitemap
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
사이트맵 닫기
Language
KOR
ENG
LinkedIn
YouTube
ESG
SK careers
C/S
SK ethics
Q
U
I
C
K
PR
SK bioscience company news updates
PR
About Us
Science & Technology
Business
ESG
IR
PR
Press Releases
Press Releases
Media Zoom
Brochure
CI Guideline
Press releases
SK bioscience and Hilleman Laboratories Announce Joint Development of Second -Generation Zaire Ebola Virus Vaccine
2023.11.22
Africa CDC Director General Visits SK bioscience to Discuss Vaccine Localization in Africa
2023.11.05
Updated Novavax COVID-19 Vaccine Is Submitted for Emergency Use Authorization in the Republic of Korea
2023.10.20
SK bioscience Implements Laboratory Information Management System First Among South Korean Vaccine Companies
2023.09.20
Prime Minister of the Republic of Serbia Visits SK bioscience to Establish Partnership for Vaccine Localization
2023.09.08
SK bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine
2023.08.24
SK bioscience Begins First Shipment of SKYCellflu for 2023-2024 Flu Season
2023.08.23
SK bioscience Announces Equity Investment in Novavax to Strengthen Strategic Partnership
2023.08.09
SK bioscience Donates to Help Local Community in Yecheon and Mungyeong, South Korea
2023.07.31
SK bioscience Releases 2023 ESG Report, Reaffirming Its Commitment to Sustainability
2023.07.28
처음
이전
1
2
3
4
5
6
7
8
9
10
다음
끝
